Cargando…

Neo-Antigen mRNA Vaccines

The interest in therapeutic cancer vaccines has caught enormous attention in recent years due to several breakthroughs in cancer research, among which the finding that successful checkpoint blockade treatments reinvigorate neo-antigen-specific T cells and that successful adoptive cell therapies are...

Descripción completa

Detalles Bibliográficos
Autores principales:	Esprit, Arthur, de Mey, Wout, Bahadur Shahi, Rajendra, Thielemans, Kris, Franceschini, Lorenzo, Breckpot, Karine
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7766040/ https://www.ncbi.nlm.nih.gov/pubmed/33353155 http://dx.doi.org/10.3390/vaccines8040776

Ejemplares similares

RNA in Cancer Immunotherapy: Unlocking the Potential of the Immune System
por: De Mey, Wout, et al.
Publicado: (2022)

A synthetic DNA template for fast manufacturing of versatile single epitope mRNA
por: de Mey, Wout, et al.
Publicado: (2022)

An mRNA mix redirects dendritic cells towards an antiviral program, inducing anticancer cytotoxic stem cell and central memory CD8(+) T cells
por: de Mey, Wout, et al.
Publicado: (2023)

mRNA: From a chemical blueprint for protein production to an off-the-shelf therapeutic
por: Van Lint, Sandra, et al.
Publicado: (2013)

Particle-mediated Intravenous Delivery of Antigen mRNA Results in Strong Antigen-specific T-cell Responses Despite the Induction of Type I Interferon
por: Broos, Katrijn, et al.
Publicado: (2016)

Intralymphatic mRNA vaccine induces CD8 T-cell responses that inhibit the growth of mucosally located tumours
por: Bialkowski, Lukasz, et al.
Publicado: (2016)

mRNA in cancer immunotherapy: beyond a source of antigen
por: Van Hoecke, Lien, et al.
Publicado: (2021)

Intratumoral administration of mRNA encoding a fusokine consisting of IFN-β and the ectodomain of the TGF-β receptor II potentiates antitumor immunity
por: Van der Jeught, Kevin, et al.
Publicado: (2014)

The role of SMAC mimetics in regulation of tumor cell death and immunity
por: Emeagi, Perpetua U., et al.
Publicado: (2012)

Single-Domain Antibody Nuclear Imaging Allows Noninvasive Quantification of LAG-3 Expression by Tumor-Infiltrating Leukocytes and Predicts Response of Immune Checkpoint Blockade
por: Lecocq, Quentin, et al.
Publicado: (2021)

TriMix and tumor antigen mRNA electroporated dendritic cell vaccination plus ipilimumab: link between T-cell activation and clinical responses in advanced melanoma
por: De Keersmaecker, Brenda, et al.
Publicado: (2020)

Design of an Optimized Wilms' Tumor 1 (WT1) mRNA Construct for Enhanced WT1 Expression and Improved Immunogenicity In Vitro and In Vivo
por: Benteyn, Daphné, et al.
Publicado: (2013)

Overcoming HLA restriction in clinical trials: Immune monitoring of mRNA-loaded DC therapy
por: Van Nuffel, An M.T., et al.
Publicado: (2012)

Pros and Cons of Antigen-Presenting Cell Targeted Tumor Vaccines
por: Goyvaerts, Cleo, et al.
Publicado: (2015)

Immunomodulation of the Tumor Microenvironment: Turn Foe Into Friend
por: Locy, Hanne, et al.
Publicado: (2018)

Phase II study of autologous mRNA electroporated dendritic cells (TriMixDC-MEL) in combination with Ipilimumab in patients with pretreated advanced melanoma
por: Thielemans, Kris, et al.
Publicado: (2014)

mRNA as a Therapeutics: Understanding mRNA Vaccines
por: Oğuz, Ferdi, et al.
Publicado: (2022)

mRNA Vaccine Platform: mRNA Production and Delivery
por: Litvinova, V. R., et al.
Publicado: (2023)

Identification of tumor antigens and immune subtypes of cholangiocarcinoma for mRNA vaccine development
por: Huang, Xing, et al.
Publicado: (2021)

Identification of Tumor Antigens and Immune Landscape in Glioblastoma for mRNA Vaccine Development
por: Ye, Liguo, et al.
Publicado: (2021)

Dissecting Tumor Antigens and Immune Subtypes of Glioma to Develop mRNA Vaccine
por: Zhong, Hua, et al.
Publicado: (2021)

Identification of Tumor Antigens and Immune Subtypes of Glioblastoma for mRNA Vaccine Development
por: Lin, Han, et al.
Publicado: (2022)

Tumor-antigens and immune landscapes identification for prostate adenocarcinoma mRNA vaccine
por: Zheng, Xiaonan, et al.
Publicado: (2021)

Identification of tumor antigens and immune subtypes of glioma for mRNA vaccine development
por: Chen, Zhuohui, et al.
Publicado: (2022)

Discovery and characterization of tumor antigens in hepatocellular carcinoma for mRNA vaccine development
por: Fu, Jiantao, et al.
Publicado: (2022)

Analysis of melanoma tumor antigens and immune subtypes for the development of mRNA vaccine
por: Ping, Haiqin, et al.
Publicado: (2022)

Identification of Potential Antigens for Developing mRNA Vaccine for Immunologically Cold Mesothelioma
por: Zhang, Shichao, et al.
Publicado: (2022)

Intranodal administration of mRNA encoding nucleoprotein provides cross-strain immunity against influenza in mice
por: Joe, Patrick Tjok, et al.
Publicado: (2019)

Treatment with mRNA coding for the necroptosis mediator MLKL induces antitumor immunity directed against neo-epitopes
por: Van Hoecke, Lien, et al.
Publicado: (2018)

Therapeutic anti-tumor immunity directed against neo-epitopes by intratumor delivery of mRNA encoding MLKL
por: Van Hoecke, Lien, et al.
Publicado: (2018)

Identifying Potential Tumor Antigens and Antigens-Related Subtypes in Hepatocellular Carcinoma for mRNA Vaccine Development
por: Liao, Weiran, et al.
Publicado: (2022)

Dangers of mRNA vaccines
por: Ali, Tahoora, et al.
Publicado: (2021)

mRNA-Based Vaccines
por: Kowalzik, Frank, et al.
Publicado: (2021)

Advances in mRNA vaccines
por: Li, Mengyun, et al.
Publicado: (2022)

mRNA vaccines: the most recent clinical applications of synthetic mRNA
por: Kwon, Suji, et al.
Publicado: (2022)

Myocarditis following COVID‐19 mRNA (mRNA‐1273) vaccination
por: Chellapandian, Suresh Babu, et al.
Publicado: (2022)

Identification of tumor antigens and immune subtypes of pancreatic adenocarcinoma for mRNA vaccine development
por: Huang, Xing, et al.
Publicado: (2021)

Recognition of Tumor-Associated Antigens and Immune Subtypes in Glioma for mRNA Vaccine Development
por: Ma, Shuai, et al.
Publicado: (2021)

Identification of Tumor Antigens and Immune Subtypes in Lung Adenocarcinoma for mRNA Vaccine Development
por: Xu, Ran, et al.
Publicado: (2022)

Construction and Immunogenicity of Modified mRNA-Vaccine Variants Encoding Influenza Virus Antigens
por: Starostina, Ekaterina V., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_8k7nmbgvrguaksefl8gdm0mp06